Post-CA Neuroprotection With Magnesium

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-85
SponsorNYU Langone Health

About this trial

The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.

Eligibility criteria

Qualifiers

Documented post-cardiac arrest patient with Return of Spontaneous Circulation (ROSC) achieved <2 hours prior to recruitment

Disqualifiers

Age < 18 years or > 85 years

Traumatic cardiac arrests

Unsustained ROSC (<20 minutes)

Patient who is responsive/able to follow motor commands within 1 hour of achieving ROSC

Trial design

Treatments tested in this trial

  • Magnesium Sulfate
  • Saline

Treatment groups

178 Participants
are divided into 2 treatment groups

Sponsors and collaborators

NYU Langone Health

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator